Kivexa

Indications for taking Kivexa.

– infection caused by the human immunodeficiency virus (HIV), as part of combined antiretroviral therapy for adults and adolescents over 12 years of age.

Method of application and dosage of Kivexa.

Therapy should be performed by a doctor with experience in HIV treatment.
Due to the impossibility of dose adjustment when using combined tablets with fixed dosages of ingredients, Kivexa should not be given to adults and adolescents whose body weight is less than 40 kg.
Kivexa tablets can be taken regardless of food intake.

Combination preparations with fixed doses of ingredients should not be used when there may be a need for dose adjustment, for example, with a CK of less than 50 ml / min, as well as with liver failure. In the event of discontinuation of the remedy Kivexa or if necessary, dose adjustment should be appointed as monotherapy remedies abacavir (Ziagen) or lamivudine (Epivir). In such situations, the doctor should become familiar with the instructions for the use of these medications.
This remedy is prescribed for one tablet one time / day daily for adults and children 12 years of age and older.
It is not recommended to use Kivexa for the treatment of children under the age of 12 due to the lack of dose correction capability. For the selection of therapy, physicians are advised to consult the instructions for the use of lamivudine and abacavir.
The pharmacokinetics of abacavir and lamivudine in patients older than 65 years have not been studied. In treating elderly patients, the increased incidence of liver, kidney, heart, and other comorbid conditions, as well as the use of other medications, should be considered.
While patients with impaired renal function do not need a dose adjustment for abacavir, the dose of lamivudine should be reduced in proportion to the decrease in creatinine clearance. In this regard, it is not recommended to use the remedy Kivexa at CC less than 50 ml / min.

Patients with impaired hepatic function.

Patients with a mild liver function disorder may need a reduction in the dose of abacavir. In connection with the impossibility of reducing the dose with the use of the remedy Kivexa, a remedy containing only abacavir should be used. The remedy is contraindicated in patients with moderate and severe liver dysfunction.